Expertise in
11
conditions

Dr. John Wrangle

Oncology
MUSC University Hospital
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
11
conditions
MUSC University Hospital
171 Ashley Ave, 
Charleston, SC 

Overview

John Wrangle is an Oncologist in Charleston, South Carolina. Dr. Wrangle is highly rated in 11 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in GA

Hospital Affiliations

Musc Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

MUSC University Hospital
171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Atezolizumab, Cisplatin, Pemetrexed Disodium
Study Phase: Phase 1
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: CLN-081
Study Phase: Phase 1/Phase 2
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Biological
Study Drugs: ALT-803, Nivolumab
Study Phase: Phase 1/Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study
Enrollment Status: Completed
Publish Date: December 17, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 14 Less Clinical Trials

39 Total Publications

County-Level Cervical Cancer Screening Coverage and Differences in Incidence and Mortality.
County-Level Cervical Cancer Screening Coverage and Differences in Incidence and Mortality.
Journal: JAMA network open
Published: August 13, 2025
Similar Doctors
Gerard Silvestri
Expertise in
17
conditions
Dr. Gerard Silvestri
Oncology
Expertise in
17
conditions
Dr. Gerard Silvestri
Oncology

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gerard Silvestri is an Oncologist in Charleston, South Carolina. Dr. Silvestri is highly rated in 17 conditions, according to our data. His top areas of expertise are Lung Nodules, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Advanced Bronchoscopy.

Expertise in
22
conditions
Dr. Rodney Schlosser
Oncology
Expertise in
22
conditions
Dr. Rodney Schlosser
Oncology

Carolina Family Care Inc.

1600 Midtown Ave, 
Mount Pleasant, SC 
 (6.6 miles away)
843-876-8282
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rodney Schlosser is an Oncologist in Mount Pleasant, South Carolina. Dr. Schlosser is highly rated in 22 conditions, according to our data. His top areas of expertise are Sinusitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Cerebrospinal Fluid Leak, Septoplasty, and Endoscopy.

Expertise in
44
conditions
Dr. Scott Lindhorst
Oncology
Expertise in
44
conditions
Dr. Scott Lindhorst
Oncology

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Lindhorst is an Oncologist in Charleston, South Carolina. Dr. Lindhorst is highly rated in 44 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy.

Frequently Asked Questions about Dr. John Wrangle

How do I make an appointment with Dr. John Wrangle?

You can book an appointment with Dr. John Wrangle by calling their office at 843-792-1414. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Wrangle a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Wrangle is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Wrangle specialize in?

While Dr. John Wrangle is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John Wrangle participate in research or clinical trials?

Yes. Dr. John Wrangle has published 39 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. John Wrangle's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John Wrangle accept my insurance?

Dr. John Wrangle accepts most major insurance plans, including Absolute Total Care South Carolina and Blue Cross Blue Shield. We recommend calling the office directly at 843-792-1414 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wrangle's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile